Tag: <span>JAK inhibitor</span>

Home / JAK inhibitor
Post

FDA Approves JAK Inhibitor Deuruxolitinib for Alopecia Areata

The US Food and Drug Administration (FDA) has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib for the treatment of adults with severe alopecia areata. The development, which was announced in a July 25, 2024, news release from the drug’s manufacturer Sun Pharma, is based on data from two pivotal randomized, double-blind, placebo-controlled phase 3...

Post

Treating sarcoidosis with JAK inhibitor shows promise in clinical trial

Every patient in a Yale clinical trial of a new treatment for the disfiguring disease sarcoidosis saw an improvement in their skin — and more than half showed improvement in affected internal organs. Sarcoidosis is a disease affecting four out of every 10,000 people in the United States. In sarcoidosis, abnormal collections of immune cells called granulomas...